# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Wilma Mankiller (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML052-SYN-TD
- Date: 1980-03-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rena Hawkfeather-Lindqvist, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for new patient with six weeks of drooping eyelids, double vision and fatigable weakness while recovering from a car crash: examination, ice pack test, breathing measurements, baseline tests, a pyridostigmine trial, kidney screening, and neuromuscular neurology referral. **S**

## Objective

Hemoglobin: 12.8 g/dL; White cell count: 6.9 10*3/uL; Platelets: 262 10*3/uL; Sodium: 139 mmol/L; Potassium: 4.2 mmol/L; Glucose: 88 mg/dL; Creatinine: 0.78 mg/dL; eGFR (CKD-EPI 1975): 102 mL/min/1.73 m²; Calcium: 9.4 mg/dL; ALT: 18 U/L; AST: 21 U/L; Albumin: 4.2 g/dL; TSH: 1.9 mIU/L; Hemoglobin A1c: 5.3%; Urine albumin-to-creatinine ratio: 14 mg/g; 25-hydroxyvitamin D: 31 ng/mL; Forced vital capacity (seated): 3.3 L; PHQ-9: 7. All results are synthetic.

BP 126/82 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 61.8 kg; BMI 23.3 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Drooping eyelids and double vision for six weeks, worse in the evening, with fatigable weakness of the arms and neck, tiring when chewing and a nasal voice after long talks; a disorder of the neuromuscular junction suspected; Autosomal dominant polycystic kidney disease (hereditary, as she has described it), with normal kidney function; to be staged; Recovery from major trauma in a head-on car crash last year: fractures of both legs, ribs and face, with many operations; walks independently, with a cane on rough ground. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Started: Pyridostigmine bromide 30 mg oral tablet, one tablet three times daily with meals as a trial; take 30 to 45 minutes before eating **S**
- Continued without change: Acetaminophen 500 mg oral tablet, one or two tablets up to three times daily as needed for leg pain **S**

## Plan

- Neuromuscular neurology consultation within two weeks for suspected generalized myasthenia gravis: diagnosis, immunotherapy, thymectomy and safety. Guideline: Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020); Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016) **S**
- Diagnostic tests: acetylcholine receptor binding antibodies (MuSK antibodies if negative), repetitive nerve stimulation (single-fiber EMG if unclear), CT of the chest with contrast for thymoma, TSH, and seated FVC with negative inspiratory force. Guideline: Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020); Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016) **S**
- Safety: pyridostigmine 30 mg three times daily as a trial; warning signs of myasthenic crisis (breathlessness lying flat, weak cough, trouble swallowing, slurred speech) with emergency care the same day; a wallet card and the list of medicines to avoid, including fluoroquinolones, aminoglycosides, macrolides, magnesium by vein, beta-blockers and telithromycin. Guideline: Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016); Cautionary Drugs (medicines that may worsen myasthenia gravis) (2026) **S**
- Kidney care for her hereditary polycystic kidney disease: kidney ultrasound with total kidney volume, eGFR and urine albumin, home blood pressure readings, 2 to 3 liters of water a day spread through the day, less salt, and acetaminophen instead of NSAIDs. Guideline: KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int 2025;107(2S):S1-S239 (2025) **S**
- Culturally safe care: laboratory work at a Cherokee Nation Health Services clinic near her home, results shared with this clinic; time given to explain each test and medicine plainly; her own Cherokee medicine respected, with any plant medicine shared so that interactions can be checked, and nothing further asked. Guideline: Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016); Cherokee Nation Health Services (2026) **S**
